Rajesh B. Parekh - 13 May 2021 Form 4 Insider Report for Eloxx Pharmaceuticals, Inc.

Role
Director
Signature
/s/ Neil S. Belloff, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
13 May 2021
Net transactions value
+$3,329,999
Form type
4
Filing time
17 May 2021, 09:22:11 UTC
Next filing
20 May 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ELOX Common Stock Purchase $114,448 +84,776 +97% $1.35 171,807 13 May 2021 See footnote F1, F2
transaction ELOX Common Stock Purchase $3,215,552 +2,381,890 +97% $1.35 4,827,129 13 May 2021 See footnote F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that is expected to close on May 18, 2021.
F2 Held directly by Advent Life Sciences LLP. The Reporting Person is a general partner of Advent Life Sciences LLP. The Reporting Person disclaims beneficial ownership of the reported shares, except to the extent of any pecuniary interest therein.
F3 Held directly by Advent Life Sciences Fund II LP. Advent Life Sciences LLP is the manager of Advent Life Sciences Fund II LP and the Reporting Person is a general partner of Advent Life Sciences LLP. The Reporting Person disclaims beneficial ownership of the reported shares, except to the extent of any pecuniary interest therein.